lestaurtinib has been researched along with Cancer of Pancreas in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (66.67) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berlin, J; Chan, E; Holen, KD; Lockhart, AC; Mulkerin, D; Rothenberg, M; Thomas, J | 1 |
Dionne, CA; Klein-Szanto, AJ; Miknyoczki, SJ; Ruggeri, BA | 1 |
Chang, H; Dionne, CA; Klein-Szanto, A; Miknyoczki, SJ; Ruggeri, BA | 1 |
1 trial(s) available for lestaurtinib and Cancer of Pancreas
Article | Year |
---|---|
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2008 |
2 other study(ies) available for lestaurtinib and Cancer of Pancreas
Article | Year |
---|---|
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carbazoles; Enzyme Inhibitors; Female; Furans; Humans; Indoles; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor Protein-Tyrosine Kinases; Trachea | 1999 |
The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Carbazoles; Drug Screening Assays, Antitumor; Female; Furans; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Rats; Receptor, trkA; Time Factors; Trachea; Treatment Outcome; Tumor Cells, Cultured | 1999 |